SCHEMBL10189449

SCHEMBL10189449

COCCOC(=O)Nc1cc(-c2csnc2-c2cc(C)c(OC)c(OC)c2)ccc1OC

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
MAPT P10636 5/20 0.36
LMNA P02545 2/20 0.36
ADORA3 P0DMS8 1/20 0.35
ADORA2B P29275 1/20 0.35
CSNK2A2 P19784 1/20 0.35
CSNK2A1 P68400 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
POLB P06746 2/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL617828 0.94 RXFP1 (0.40) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10189450 0.93 ALDH1A1 (0.39) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL12118594 0.87 MAPT (0.41) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10189443 0.87 POLB (0.41) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10189237 0.86 ALDH1A1 (0.44) SMN1; SMN2KDM4EALDH1A1HSD17B10RXFP1
SCHEMBL12338915 0.84 MAPT (0.37) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10189445 0.84 NPSR1 (0.47) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10189442 0.83 NPSR1 (0.41) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10189439 0.83 NPSR1 (0.39) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10189378 0.82 LMNA (0.38) ALDH1A1HPGDHSD17B10RXFP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 SMN1; SMN2 3188/4885KDM4E 2492/4885ALDH1A1 1872/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 SMN1; SMN2 3188/4885KDM4E 2492/4885ALDH1A1 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.